Filing Details

Accession Number:
0001395064-20-000082
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-03 06:08:55
Reporting Period:
2020-06-01
Accepted Time:
2020-06-03 06:08:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1693415 Translate Bio Inc. TBIO Pharmaceutical Preparations (2834) 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1395064 Takeda Pharmaceutical Co Ltd 1-1, Nihonbashi-Honcho 2-Chome
Chuo-Ku, Tokyo M0 103-8668
No No Yes No
1745009 Shire Human Genetic Therapies, Inc. 300 Shire Way
Lexington MA 02421
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-06-01 107,072 $19.85 6,971,873 No 4 S Direct
Common Stock Disposition 2020-06-01 1,400 $20.53 6,970,473 No 4 S Direct
Common Stock Disposition 2020-06-02 100,389 $19.75 6,870,084 No 4 S Direct
Common Stock Disposition 2020-06-02 5,006 $20.02 6,865,078 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Weighted average of sales prices. Actual prices range from $19.40 to $20.25. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
  2. This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
  3. These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.
  4. Weighted average of sales prices. Actual prices range from $20.40 to $20.56. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
  5. Weighted average of sales prices. Actual prices range from $19.05 to $19.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
  6. Weighted average of sales prices. Actual prices range from $20.00 to $20.05. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.